{"transactions":[{"id":4640214,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":46857,"kind":"person","name":"GREGORY JULIA P","position":1,"cik":"0001226675","reported_name":"GREGORY JULIA P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-10-14T20:11:39.000Z","date":"2026-10-14","kind":"exercise","planned":false,"acquired":false,"shares":22583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019 until the option was fully vested on August 12, 2023."}],"balance_after":0,"derivative":{"exercise_price":1.86,"expiration_date":"2029-12-22","underlying":"Common Stock","underlying_shares":22583},"source":{"system":"sec-edgar","filing":"0001226675-26-000006","document":"wk-form4_1792008695.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000122667526000006/wk-form4_1792008695.xml","form_type":"4"}},{"id":4640213,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":46857,"kind":"person","name":"GREGORY JULIA P","position":1,"cik":"0001226675","reported_name":"GREGORY JULIA P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-14T20:11:39.000Z","date":"2026-10-14","kind":"sale","planned":false,"acquired":false,"shares":22583,"price":23.4038,"value":528528.0154,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.34 and the highest price at which shares were sold was $23.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":10750,"source":{"system":"sec-edgar","filing":"0001226675-26-000006","document":"wk-form4_1792008695.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000122667526000006/wk-form4_1792008695.xml","form_type":"4"}},{"id":4640212,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":46857,"kind":"person","name":"GREGORY JULIA P","position":1,"cik":"0001226675","reported_name":"GREGORY JULIA P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-14T20:11:39.000Z","date":"2026-10-14","kind":"exercise","planned":false,"acquired":true,"shares":22583,"price":1.86,"value":42004.38,"ownership":{"direct":true},"balance_after":33333,"source":{"system":"sec-edgar","filing":"0001226675-26-000006","document":"wk-form4_1792008695.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000122667526000006/wk-form4_1792008695.xml","form_type":"4"}},{"id":4629134,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-10-02T21:21:03.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":false,"shares":5786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":111251,"derivative":{"exercise_price":8.72,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":5786},"source":{"system":"sec-edgar","filing":"0001817199-26-000032","document":"wk-form4_1790976061.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000032/wk-form4_1790976061.xml","form_type":"4"}},{"id":4629133,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-10-02T21:21:03.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":5786,"price":23.1851,"value":134148.9886,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":9110,"source":{"system":"sec-edgar","filing":"0001817199-26-000032","document":"wk-form4_1790976061.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000032/wk-form4_1790976061.xml","form_type":"4"}},{"id":4629132,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-10-02T21:21:03.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":true,"shares":5786,"price":8.72,"value":50453.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":14896,"source":{"system":"sec-edgar","filing":"0001817199-26-000032","document":"wk-form4_1790976061.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000032/wk-form4_1790976061.xml","form_type":"4"}},{"id":1410,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-02T23:42:42.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":false,"shares":5787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":117037,"derivative":{"exercise_price":8.72,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":5787},"source":{"system":"sec-edgar","filing":"0001817199-26-000030","document":"wk-form4_1788392559.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000030/wk-form4_1788392559.xml","form_type":"4"}},{"id":1409,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-02T23:42:42.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":400,"price":26.6375,"value":10655.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $26.46 and the highest price at which shares were sold was $26.73. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":9110,"source":{"system":"sec-edgar","filing":"0001817199-26-000030","document":"wk-form4_1788392559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000030/wk-form4_1788392559.xml","form_type":"4"}},{"id":1408,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-02T23:42:42.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":5387,"price":25.6947,"value":138417.3489,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $25.41 and the highest price at which shares were sold was $26.23. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":9510,"source":{"system":"sec-edgar","filing":"0001817199-26-000030","document":"wk-form4_1788392559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000030/wk-form4_1788392559.xml","form_type":"4"}},{"id":1407,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-02T23:42:42.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":true,"shares":5787,"price":8.72,"value":50462.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":14897,"source":{"system":"sec-edgar","filing":"0001817199-26-000030","document":"wk-form4_1788392559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000030/wk-form4_1788392559.xml","form_type":"4"}},{"id":671288,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-01T21:19:15.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":1452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023."}],"balance_after":60858,"derivative":{"exercise_price":1.86,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":1452},"source":{"system":"sec-edgar","filing":"0001817160-26-000019","document":"wk-form4_1788297552.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000019/wk-form4_1788297552.xml","form_type":"4"}},{"id":671287,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-01T21:19:15.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":1452,"price":25.47,"value":36982.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":117227,"source":{"system":"sec-edgar","filing":"0001817160-26-000019","document":"wk-form4_1788297552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000019/wk-form4_1788297552.xml","form_type":"4"}},{"id":671286,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-01T21:19:15.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":1452,"price":1.86,"value":2700.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":118679,"source":{"system":"sec-edgar","filing":"0001817160-26-000019","document":"wk-form4_1788297552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000019/wk-form4_1788297552.xml","form_type":"4"}},{"id":695816,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-05T22:59:04.000Z","date":"2026-08-05","kind":"exercise","planned":true,"acquired":false,"shares":4356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023."}],"balance_after":62310,"derivative":{"exercise_price":1.86,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":4356},"source":{"system":"sec-edgar","filing":"0001817160-26-000017","document":"wk-form4_1785970741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000017/wk-form4_1785970741.xml","form_type":"4"}},{"id":695815,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T22:59:04.000Z","date":"2026-08-05","kind":"sale","planned":true,"acquired":false,"shares":4356,"price":25,"value":108900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":117227,"source":{"system":"sec-edgar","filing":"0001817160-26-000017","document":"wk-form4_1785970741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000017/wk-form4_1785970741.xml","form_type":"4"}},{"id":695814,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T22:59:04.000Z","date":"2026-08-05","kind":"exercise","planned":true,"acquired":true,"shares":4356,"price":1.86,"value":8102.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":121583,"source":{"system":"sec-edgar","filing":"0001817160-26-000017","document":"wk-form4_1785970741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000017/wk-form4_1785970741.xml","form_type":"4"}},{"id":695813,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T10:39:37.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":2611,"price":24.6415,"value":64338.9565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $24.43 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":117227,"source":{"system":"sec-edgar","filing":"0001817160-26-000015","document":"wk-form4_1785926375.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000015/wk-form4_1785926375.xml","form_type":"4"}},{"id":695812,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T10:39:37.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":23.8684,"value":35802.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.38. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":119838,"source":{"system":"sec-edgar","filing":"0001817160-26-000015","document":"wk-form4_1785926375.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000015/wk-form4_1785926375.xml","form_type":"4"}},{"id":697326,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-05T01:41:21.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":2967,"price":24.6474,"value":73128.8358,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":40166,"source":{"system":"sec-edgar","filing":"0001817217-26-000012","document":"wk-form4_1785894078.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000012/wk-form4_1785894078.xml","form_type":"4"}},{"id":697325,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-05T01:41:21.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":1794,"price":23.8911,"value":42860.6334,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":43133,"source":{"system":"sec-edgar","filing":"0001817217-26-000012","document":"wk-form4_1785894078.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000012/wk-form4_1785894078.xml","form_type":"4"}},{"id":698960,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-03T21:51:59.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":5787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":122824,"derivative":{"exercise_price":8.72,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":5787},"source":{"system":"sec-edgar","filing":"0001817199-26-000028","document":"wk-form4_1785793916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000028/wk-form4_1785793916.xml","form_type":"4"}},{"id":698959,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-03T21:51:59.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":16589,"price":23.0489,"value":382358.2021,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $22.67 and the highest price at which shares were sold was $23.30. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":9110,"source":{"system":"sec-edgar","filing":"0001817199-26-000028","document":"wk-form4_1785793916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000028/wk-form4_1785793916.xml","form_type":"4"}},{"id":698958,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-03T21:51:59.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":5787,"price":8.72,"value":50462.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":25699,"source":{"system":"sec-edgar","filing":"0001817199-26-000028","document":"wk-form4_1785793916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000028/wk-form4_1785793916.xml","form_type":"4"}},{"id":700736,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:58:55.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":39303,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3572},"source":{"system":"sec-edgar","filing":"0001817217-26-000010","document":"wk-form4_1785448733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000010/wk-form4_1785448733.xml","form_type":"4"}},{"id":700735,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:58:55.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":20009,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817217-26-000010","document":"wk-form4_1785448733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000010/wk-form4_1785448733.xml","form_type":"4"}},{"id":700734,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:58:55.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":11250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817217-26-000010","document":"wk-form4_1785448733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000010/wk-form4_1785448733.xml","form_type":"4"}},{"id":700733,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:58:55.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":2845,"price":23.3828,"value":66524.066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":44927,"source":{"system":"sec-edgar","filing":"0001817217-26-000010","document":"wk-form4_1785448733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000010/wk-form4_1785448733.xml","form_type":"4"}},{"id":700732,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:58:55.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47772,"source":{"system":"sec-edgar","filing":"0001817217-26-000010","document":"wk-form4_1785448733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000010/wk-form4_1785448733.xml","form_type":"4"}},{"id":700731,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:58:55.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44200,"source":{"system":"sec-edgar","filing":"0001817217-26-000010","document":"wk-form4_1785448733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000010/wk-form4_1785448733.xml","form_type":"4"}},{"id":700730,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:58:55.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":41342,"source":{"system":"sec-edgar","filing":"0001817217-26-000010","document":"wk-form4_1785448733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000010/wk-form4_1785448733.xml","form_type":"4"}},{"id":700729,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:56:08.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":39303,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3572},"source":{"system":"sec-edgar","filing":"0001817199-26-000026","document":"wk-form4_1785448565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000026/wk-form4_1785448565.xml","form_type":"4"}},{"id":700728,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:56:08.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":20009,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817199-26-000026","document":"wk-form4_1785448565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000026/wk-form4_1785448565.xml","form_type":"4"}},{"id":700727,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:56:08.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":11250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817199-26-000026","document":"wk-form4_1785448565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000026/wk-form4_1785448565.xml","form_type":"4"}},{"id":700726,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:56:08.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":3847,"price":23.3828,"value":89953.6316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":19912,"source":{"system":"sec-edgar","filing":"0001817199-26-000026","document":"wk-form4_1785448565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000026/wk-form4_1785448565.xml","form_type":"4"}},{"id":700725,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:56:08.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":23759,"source":{"system":"sec-edgar","filing":"0001817199-26-000026","document":"wk-form4_1785448565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000026/wk-form4_1785448565.xml","form_type":"4"}},{"id":700724,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:56:08.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20187,"source":{"system":"sec-edgar","filing":"0001817199-26-000026","document":"wk-form4_1785448565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000026/wk-form4_1785448565.xml","form_type":"4"}},{"id":700723,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:56:08.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17329,"source":{"system":"sec-edgar","filing":"0001817199-26-000026","document":"wk-form4_1785448565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000026/wk-form4_1785448565.xml","form_type":"4"}},{"id":700743,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":39303,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3572},"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700742,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":20009,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700741,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":11250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700740,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":3847,"price":23.3828,"value":89953.6316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":121338,"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700739,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125185,"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700738,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":121613,"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700737,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":118755,"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":718208,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-02T22:02:59.000Z","date":"2026-07-02","kind":"exercise","planned":true,"acquired":false,"shares":5787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":128611,"derivative":{"exercise_price":8.72,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":5787},"source":{"system":"sec-edgar","filing":"0001817199-26-000024","document":"wk-form4_1783029777.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000024/wk-form4_1783029777.xml","form_type":"4"}},{"id":718207,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-02T22:02:59.000Z","date":"2026-07-02","kind":"exercise","planned":true,"acquired":false,"shares":5221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023."}],"balance_after":0,"derivative":{"exercise_price":1.86,"expiration_date":"2029-09-30","underlying":"Common Stock","underlying_shares":5221},"source":{"system":"sec-edgar","filing":"0001817199-26-000024","document":"wk-form4_1783029777.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000024/wk-form4_1783029777.xml","form_type":"4"}},{"id":718206,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:02:59.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":11008,"price":23.5616,"value":259366.0928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.23 and the highest price at which shares were sold was $24.16. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":13579,"source":{"system":"sec-edgar","filing":"0001817199-26-000024","document":"wk-form4_1783029777.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000024/wk-form4_1783029777.xml","form_type":"4"}},{"id":718205,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:02:59.000Z","date":"2026-07-02","kind":"exercise","planned":true,"acquired":true,"shares":5787,"price":8.72,"value":50462.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":24587,"source":{"system":"sec-edgar","filing":"0001817199-26-000024","document":"wk-form4_1783029777.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000024/wk-form4_1783029777.xml","form_type":"4"}},{"id":718204,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:02:59.000Z","date":"2026-07-02","kind":"exercise","planned":true,"acquired":true,"shares":5221,"price":1.86,"value":9711.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":18800,"source":{"system":"sec-edgar","filing":"0001817199-26-000024","document":"wk-form4_1783029777.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000024/wk-form4_1783029777.xml","form_type":"4"}},{"id":726505,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-25T22:49:10.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":5394,"price":20,"value":107880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":115005,"source":{"system":"sec-edgar","filing":"0001817160-26-000010","document":"wk-form4_1782427748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000010/wk-form4_1782427748.xml","form_type":"4"}},{"id":726504,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-25T22:38:05.000Z","date":"2026-06-25","kind":"exercise","planned":true,"acquired":false,"shares":15602,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027."}],"balance_after":134398,"derivative":{"exercise_price":8.72,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":15602},"source":{"system":"sec-edgar","filing":"0001817199-26-000022","document":"wk-form4_1782427081.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000022/wk-form4_1782427081.xml","form_type":"4"}},{"id":726503,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-25T22:38:05.000Z","date":"2026-06-25","kind":"exercise","planned":true,"acquired":false,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 1/48 of the total shares monthly beginning February 18, 2020, until the option was fully vested on January 18, 2024."}],"balance_after":0,"derivative":{"exercise_price":7.26,"expiration_date":"2030-02-26","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001817199-26-000022","document":"wk-form4_1782427081.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000022/wk-form4_1782427081.xml","form_type":"4"}},{"id":726502,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-25T22:38:05.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":28935,"price":20.0624,"value":580505.544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.40. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":13579,"source":{"system":"sec-edgar","filing":"0001817199-26-000022","document":"wk-form4_1782427081.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000022/wk-form4_1782427081.xml","form_type":"4"}},{"id":726501,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-25T22:38:05.000Z","date":"2026-06-25","kind":"exercise","planned":true,"acquired":true,"shares":15602,"price":8.72,"value":136049.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":42514,"source":{"system":"sec-edgar","filing":"0001817199-26-000022","document":"wk-form4_1782427081.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000022/wk-form4_1782427081.xml","form_type":"4"}},{"id":726500,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-25T22:38:05.000Z","date":"2026-06-25","kind":"exercise","planned":true,"acquired":true,"shares":13333,"price":7.26,"value":96797.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":26912,"source":{"system":"sec-edgar","filing":"0001817199-26-000022","document":"wk-form4_1782427081.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000022/wk-form4_1782427081.xml","form_type":"4"}},{"id":755016,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-02T23:14:20.000Z","date":"2026-06-02","kind":"exercise","planned":true,"acquired":false,"shares":3422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023."}],"balance_after":5221,"derivative":{"exercise_price":1.86,"expiration_date":"2029-09-30","underlying":"Common Stock","underlying_shares":3422},"source":{"system":"sec-edgar","filing":"0001817199-26-000020","document":"wk-form4_1780442058.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000020/wk-form4_1780442058.xml","form_type":"4"}},{"id":755015,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-02T23:14:20.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":8148,"price":16.5995,"value":135252.726,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.35 and the highest price at which shares were sold was $17.10. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":13579,"source":{"system":"sec-edgar","filing":"0001817199-26-000020","document":"wk-form4_1780442058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000020/wk-form4_1780442058.xml","form_type":"4"}},{"id":755014,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-02T23:14:20.000Z","date":"2026-06-02","kind":"exercise","planned":true,"acquired":true,"shares":3422,"price":1.86,"value":6364.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":21727,"source":{"system":"sec-edgar","filing":"0001817199-26-000020","document":"wk-form4_1780442058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000020/wk-form4_1780442058.xml","form_type":"4"}},{"id":776958,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":15694,"kind":"person","name":"Silva Paul M","position":1,"cik":"0001446372","reported_name":"Silva Paul M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:56:53.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001446372-26-000002","document":"wk-form4_1778882211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446372/000144637226000002/wk-form4_1778882211.xml","form_type":"4"}},{"id":776701,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":46815,"kind":"person","name":"Saltzman Edward C","position":1,"cik":"0001946233","reported_name":"Saltzman Edward C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:55:29.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001946233-26-000002","document":"wk-form4_1778882126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000194623326000002/wk-form4_1778882126.xml","form_type":"4"}},{"id":776907,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":34155,"kind":"person","name":"Reinsdorf Judith A","position":1,"cik":"0001305361","reported_name":"Reinsdorf Judith A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:52:59.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001305361-26-000002","document":"wk-form4_1778881977.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1305361/000130536126000002/wk-form4_1778881977.xml","form_type":"4"}},{"id":776700,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":38756,"kind":"person","name":"Lacey David L.","position":1,"cik":"0001734422","reported_name":"Lacey David L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:51:31.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001734422-26-000002","document":"wk-form4_1778881888.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000173442226000002/wk-form4_1778881888.xml","form_type":"4"}},{"id":776699,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":44129,"kind":"person","name":"Kapur Anil","position":1,"cik":"0001730703","reported_name":"Kapur Anil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:49:05.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001730703-26-000002","document":"wk-form4_1778881743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000173070326000002/wk-form4_1778881743.xml","form_type":"4"}},{"id":776698,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:46:18.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001741836-26-000004","document":"wk-form4_1778881574.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000174183626000004/wk-form4_1778881574.xml","form_type":"4"}},{"id":776697,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":20734,"kind":"person","name":"Baynes Roy D.","position":1,"cik":"0001680739","reported_name":"Baynes Roy D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:42:16.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001680739-26-000010","document":"wk-form4_1778881334.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000168073926000010/wk-form4_1778881334.xml","form_type":"4"}},{"id":776850,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":46857,"kind":"person","name":"GREGORY JULIA P","position":1,"cik":"0001226675","reported_name":"GREGORY JULIA P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:37:20.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001226675-26-000004","document":"wk-form4_1778881038.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1226675/000122667526000004/wk-form4_1778881038.xml","form_type":"4"}},{"id":791820,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T23:53:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":582,"price":17.1751,"value":9995.9082,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $17.11 and the highest price at which shares were sold was $17.22. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":37592,"source":{"system":"sec-edgar","filing":"0001817217-26-000008","document":"wk-form4_1778025219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000008/wk-form4_1778025219.xml","form_type":"4"}},{"id":791819,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T23:53:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":13473,"price":16.5756,"value":223323.0588,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.11 and the highest price at which shares were sold was $17.10. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":38174,"source":{"system":"sec-edgar","filing":"0001817217-26-000008","document":"wk-form4_1778025219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000008/wk-form4_1778025219.xml","form_type":"4"}},{"id":793917,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-04T22:10:30.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":8148,"price":16.9624,"value":138209.6352,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.78 and the highest price at which shares were sold was $17.26. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":18305,"source":{"system":"sec-edgar","filing":"0001817199-26-000018","document":"wk-form4_1777932626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000018/wk-form4_1777932626.xml","form_type":"4"}},{"id":795794,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-01T21:50:20.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5394,"price":16.7606,"value":90406.6764,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.26 and the highest price at which shares were sold was $16.97. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":26453,"source":{"system":"sec-edgar","filing":"0001817199-26-000016","document":"wk-form4_1777672218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000016/wk-form4_1777672218.xml","form_type":"4"}},{"id":796944,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:38:22.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":22867,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817217-26-000006","document":"wk-form4_1777585100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000006/wk-form4_1777585100.xml","form_type":"4"}},{"id":796943,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:38:22.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817217-26-000006","document":"wk-form4_1777585100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000006/wk-form4_1777585100.xml","form_type":"4"}},{"id":796942,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:38:22.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001817217-26-000006","document":"wk-form4_1777585100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000006/wk-form4_1777585100.xml","form_type":"4"}},{"id":796941,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:38:22.000Z","date":"2026-04-30","kind":"sale","planned":false,"acquired":false,"shares":2388,"price":16.6453,"value":39748.9764,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":51647,"source":{"system":"sec-edgar","filing":"0001817217-26-000006","document":"wk-form4_1777585100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000006/wk-form4_1777585100.xml","form_type":"4"}},{"id":796940,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:38:22.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":54035,"source":{"system":"sec-edgar","filing":"0001817217-26-000006","document":"wk-form4_1777585100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000006/wk-form4_1777585100.xml","form_type":"4"}},{"id":796939,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:38:22.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51177,"source":{"system":"sec-edgar","filing":"0001817217-26-000006","document":"wk-form4_1777585100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000006/wk-form4_1777585100.xml","form_type":"4"}},{"id":796938,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:38:22.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47427,"source":{"system":"sec-edgar","filing":"0001817217-26-000006","document":"wk-form4_1777585100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000006/wk-form4_1777585100.xml","form_type":"4"}},{"id":796951,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:37:50.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":22867,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817199-26-000014","document":"wk-form4_1777585068.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000014/wk-form4_1777585068.xml","form_type":"4"}},{"id":796950,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:37:50.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817199-26-000014","document":"wk-form4_1777585068.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000014/wk-form4_1777585068.xml","form_type":"4"}},{"id":796949,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:37:50.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001817199-26-000014","document":"wk-form4_1777585068.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000014/wk-form4_1777585068.xml","form_type":"4"}},{"id":796948,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:37:50.000Z","date":"2026-04-30","kind":"sale","planned":false,"acquired":false,"shares":3214,"price":16.6453,"value":53497.9942,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":31847,"source":{"system":"sec-edgar","filing":"0001817199-26-000014","document":"wk-form4_1777585068.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000014/wk-form4_1777585068.xml","form_type":"4"}},{"id":796947,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:37:50.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35061,"source":{"system":"sec-edgar","filing":"0001817199-26-000014","document":"wk-form4_1777585068.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000014/wk-form4_1777585068.xml","form_type":"4"}},{"id":796946,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:37:50.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32203,"source":{"system":"sec-edgar","filing":"0001817199-26-000014","document":"wk-form4_1777585068.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000014/wk-form4_1777585068.xml","form_type":"4"}},{"id":796945,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:37:50.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28453,"source":{"system":"sec-edgar","filing":"0001817199-26-000014","document":"wk-form4_1777585068.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000014/wk-form4_1777585068.xml","form_type":"4"}},{"id":796958,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":22867,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796957,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796956,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796955,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"sale","planned":false,"acquired":false,"shares":3214,"price":16.6453,"value":53497.9942,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":120399,"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796954,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":123613,"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796953,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":120755,"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796952,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":117005,"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":819771,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-02T23:02:16.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":8148,"price":15.2367,"value":124148.6316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $15.00 and the highest price at which shares were sold was $15.43. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":26453,"source":{"system":"sec-edgar","filing":"0001817199-26-000012","document":"wk-form4_1775170933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000012/wk-form4_1775170933.xml","form_type":"4"}},{"id":874377,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-03T00:05:28.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":8148,"price":15.4385,"value":125792.898,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $15.16 and the highest price at which shares were sold was $15.845. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":34601,"source":{"system":"sec-edgar","filing":"0001817199-26-000010","document":"wk-form4_1772496326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000010/wk-form4_1772496326.xml","form_type":"4"}},{"id":912166,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-10T23:09:29.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":42875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":42875,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42875},"source":{"system":"sec-edgar","filing":"0001817217-26-000004","document":"wk-form4_1770764966.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000004/wk-form4_1770764966.xml","form_type":"4"}},{"id":912165,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":26681,"kind":"person","name":"van Houte Hans","position":1,"cik":"0001817217","reported_name":"van Houte Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-10T23:09:29.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":93750,"derivative":{"exercise_price":16.45,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001817217-26-000004","document":"wk-form4_1770764966.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817217/000181721726000004/wk-form4_1770764966.xml","form_type":"4"}},{"id":912168,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-10T22:55:00.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":42875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":42875,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42875},"source":{"system":"sec-edgar","filing":"0001817199-26-000008","document":"wk-form4_1770764093.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000008/wk-form4_1770764093.xml","form_type":"4"}},{"id":912167,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":1157,"kind":"person","name":"Ring Christine","position":1,"cik":"0001817199","reported_name":"Ring Christine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-10T22:55:00.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":93750,"derivative":{"exercise_price":16.45,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001817199-26-000008","document":"wk-form4_1770764093.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817199/000181719926000008/wk-form4_1770764093.xml","form_type":"4"}},{"id":912170,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-10T22:50:25.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":42875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":42875,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42875},"source":{"system":"sec-edgar","filing":"0001817160-26-000006","document":"wk-form4_1770763822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000006/wk-form4_1770763822.xml","form_type":"4"}},{"id":912169,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-10T22:50:25.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":93750,"derivative":{"exercise_price":16.45,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001817160-26-000006","document":"wk-form4_1770763822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000006/wk-form4_1770763822.xml","form_type":"4"}},{"id":912512,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":67081,"kind":"person","name":"SANDS ARTHUR T","position":1,"cik":"0001134106","reported_name":"SANDS ARTHUR T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-10T17:43:09.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":562500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":562500,"derivative":{"exercise_price":16.45,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":562500},"source":{"system":"sec-edgar","filing":"0001134106-26-000002","document":"wk-form4_1770763386.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134106/000113410626000002/wk-form4_1770763386.xml","form_type":"4"}}],"next_cursor":"2026-02-10T17:43:09.000000Z,912512"}